{"id":390888,"date":"2017-10-10T00:00:00","date_gmt":"2017-10-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0004-2017-biopharma-biosimilars-current-treatment-immunology-us-eu-2017\/"},"modified":"2026-03-31T10:49:47","modified_gmt":"2026-03-31T10:49:47","slug":"biosbi0004-2017-biopharma-biosimilars-current-treatment-immunology-us-eu-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0004-2017-biopharma-biosimilars-current-treatment-immunology-us-eu-2017\/","title":{"rendered":"Biosimilars | Current Treatment | Immunology | US\/EU | 2017"},"content":{"rendered":"<p>Immune biologics such as\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-alpha inhibitors are among the most commercially successful biopharmaceutical products in the world, presenting a lucrative opportunity for companies to develop biosimilars of these drugs. Recent launches, such as Pfizer\u2019s Inflectra (infliximab-dyyb) in the United States and Celltrion\u2019s Truxima (rituximab) in Europe, are increasing the competition within the immunology space\u2014not just with branded biologics but with the expanding number of biosimilars gaining marketing authorization. For this reason, it is critical that manufacturers\/marketers of biosimilars, as well as of branded biologics, understand which factors influence physicians\u2019 uptake of biosimilars. To this end, Decision Resources Group conducted market research with rheumatologists and gastroenterologists in France, Germany, and the United States to gain insights on physicians\u2019 attitude toward biosimilars, the drivers and barriers to biosimilar use, and the expectations for biosimilar adoption.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>Have physicians received recommendations to use biosimilars?<\/li>\n<li>Are physicians switching patients from reference brands to biosimilars?<\/li>\n<li>What factors do physicians consider when choosing among competing biosimilars?<\/li>\n<li>How are\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-alpha inhibitor and\u00a0<abbr data-original-title=\"monoclonal antibody\" title=\"\">MAb<\/abbr>\u00a0biosimilars performing, and what are physicians\u2019 expectations for their future uptake?<\/li>\n<li>What are the key drivers and barriers to the uptake of\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-alpha inhibitor and\u00a0<abbr data-original-title=\"monoclonal antibody\" title=\"\">MAb<\/abbr>biosimilars?<\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<ul>\n<li><strong>Markets covered<\/strong>: France, Germany, and the United States.<\/li>\n<li><strong>Primary research<\/strong>: Survey of 90 rheumatologists and 91 gastroenterologists.<\/li>\n<\/ul>\n<p><strong>Key companies mentioned:<\/strong><\/p>\n<ul>\n<li>Amgen<\/li>\n<li>AbbVie<\/li>\n<li>Biogen<\/li>\n<li>Celltrion<\/li>\n<li>Johnson &#038; Johnson\/Janssen<\/li>\n<li>Merck &#038; Co.\/MSD<\/li>\n<li>Mundipharma<\/li>\n<li>Novartis\/Sandoz<\/li>\n<li>Pfizer\/Hospira<\/li>\n<li>Roche\/Genentech<\/li>\n<li>Samsung Bioepis<\/li>\n<\/ul>\n<p><strong>Key drugs mentioned:<\/strong><\/p>\n<ul>\n<li>Inflectra (infliximab)<\/li>\n<li>Remsima (infliximab)<\/li>\n<li>Benepali (etanercept)<\/li>\n<li>Flixabi (infliximab)<\/li>\n<li>Truxima (rituximab)<\/li>\n<li>Enbrel (etanercept)<\/li>\n<li>Humira (adalimumab)<\/li>\n<li>Remicade (infliximab)<\/li>\n<li>Rituxan\/MabThera (rituximab)<\/li>\n<li>Simponi (golimumab)<\/li>\n<li>Cimzia (certolizumab pegol)<\/li>\n<li>Orencia (abatacept)<\/li>\n<li>Actemra\/RoActemra (tocilizumab)<\/li>\n<li>Stelara (ustekinumab)<\/li>\n<li>Entyvio (vedolizumab)<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390888","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390888\/revisions"}],"predecessor-version":[{"id":576811,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390888\/revisions\/576811"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}